Core Insights - The chairman of Ruizhi Pharmaceutical, Hu Ruilian, emphasizes the importance of finding a unique path in a competitive market, particularly during a price war in the CXO industry [3][4] - Under Hu's leadership, the company achieved a revenue of 534 million yuan, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, marking a successful turnaround [3][4] - The company is focusing on a systematic strategic layout, including comprehensive service offerings, technological innovation, and global expansion [3][4] Financial Performance - In the first half of 2025, Ruizhi Pharmaceutical reported a revenue of 534 million yuan, reflecting a 14.75% year-on-year growth [3] - The company achieved a net profit of 25.38 million yuan, successfully reversing previous losses [3] Strategic Transformation - Hu Ruilian initiated a transformation from a fragmented subcontracting model to a one-stop delivery service model, enhancing efficiency and customer satisfaction [4][5] - The new service model allows clients to specify their needs while the company manages the entire process, creating a competitive barrier in the market [5] Technological Innovation - The company has made significant advancements in technology, particularly with the launch of the micro-flow manufacturing system in collaboration with East China Normal University [6][7] - This system is expected to revolutionize drug manufacturing by significantly reducing production space and time, while also lowering costs and impurities [6][7] Market Expansion - Ruizhi Pharmaceutical is establishing a biopharmaceutical industrial park in Malaysia, which aims to serve as a bridge for Chinese pharmaceutical companies entering the ASEAN market [8] - The park is strategically positioned to access a large market of approximately 2 billion Muslims, leveraging Malaysia's authoritative halal certification [8] Global Strategy - The company has developed a clear global layout, combining a Shanghai R&D base, localized operations in Europe and the U.S., and the Malaysian industrial park to serve emerging markets [9] - This diversified approach allows Ruizhi Pharmaceutical to support both domestic biotech companies and international pharmaceutical firms [9]

胡瑞连 ◎记者 王墨璞嘉 初见睿智医药董事长胡瑞连，这位有着多次跨界创业成功经历的企业家，说话时语速平稳间透着果决。 谈及接手睿智医药的关键抉择，他回忆道："当时全行业都在打价格战，没人相信一家老牌CXO企业能 靠转型翻盘，但我始终觉得，越是红海市场，越要找到自己的专属航道。" "睿智医药有着多年医药研发及生产服务的经验积累，科学家团队很扎实，但分包服务模式已经跟不上 行业的发展了。"胡瑞连说。 胡瑞连迅速启动变革：一方面推行降本增效、开源节流，稳定管理层、重塑组织架构；另一方面大刀阔 斧重构商业模式，从"零散施工"的分包服务模式，转向"一站式交付"的整包服务模式。 "在整包服务模式下，客户只需明确需求，从靶点发现到工艺落地所有事我们一肩挑。同时，公司还能 凭借积累的专业经验，为药企研发提供针对性建议。"胡瑞连表示。 这一转型让睿智医药跳出了低价竞争的僵局。"国内能做分包服务的CXO企业有千余家，但能做全流程 整包服务的不超过五家。睿智医药通过战略重塑，构建了自身的竞争壁垒。"胡瑞连说。 2025年上半年，睿智医药实现营收5.34亿元，同比增长14.75%；实现归母净利润2538.21万元，成功扭 亏为盈。而 ...

Core Insights - Chr. Hansen, a leading probiotic research and supply company with over 150 years of history, has established a long-term strategic partnership with the well-known nutrition brand Baibeijie, allowing the application of its BB-12 and LGG strains in Baibeijie's probiotics [1][5] - This partnership follows an initial licensing agreement in 2024 and signifies a deepening of their collaboration with no time limit, indicating a permanent long-term authorization [1] Company Overview - Founded in 1874 in Copenhagen, Chr. Hansen has evolved over 150 years, focusing on "improving life through microbial science" and becoming a leader in the global probiotic sector [2] - The company has expanded from early dairy fermentation research to a comprehensive health solutions system covering probiotics, enzyme preparations, and natural colors, with products available in over 140 countries [2] Probiotic Technology - Chr. Hansen's BB-12 and LGG strains are among the most researched probiotics globally, with BB-12 demonstrating excellent acid and bile resistance, supported by over 300 clinical studies showing significant benefits for infant gut health and immunity [4] - LGG is noted for its effectiveness in balancing gut microbiota and alleviating gastrointestinal discomfort, with over 600 related scientific publications [4] - Both strains are included in China's list of approved strains for infant food, setting industry safety standards [4] Strategic Partnership - The partnership between Chr. Hansen and Baibeijie is classified as a high-standard strain licensing collaboration, ensuring strict adherence to quality and research data, preventing the mixing of strains from other sources [4][5] - This collaboration is viewed as a model of close industry chain cooperation, enhancing brand effects and benefiting Chinese consumers with high-quality probiotics [10] Market Performance - Baibeijie has shown impressive market performance since partnering with Chr. Hansen, achieving sales of 300,000 units of BB-12 and LGG probiotic powder in the past year, leading in online sales for this probiotic combination [6] - The products are clean, containing only probiotics and prebiotics without additives, suitable for all age groups and various health conditions [8] Brand Philosophy - Both companies emphasize a commitment to high-quality products, with Baibeijie focusing on sourcing from top global suppliers and investing in raw materials rather than marketing [10] - This approach contrasts with many brands that prioritize marketing over quality, resulting in inferior products at higher prices [10] - The partnership reflects a shared philosophy of producing top-tier products and advocating for long-term solutions for consumers [10]

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

Core Viewpoint - Ruizhi Pharmaceutical (300149) announced the resignation of its board secretary, Xu Jian, due to work adjustments, effective immediately upon delivery of the resignation report [1] Group 1: Management Changes - Xu Jian will continue to serve as the Vice President of the Investment Development Department at Shanghai Ruizhi Pharmaceutical Research Group after resigning [1] - Gao Yingying has been appointed as the new board secretary, with her term lasting until the end of the sixth board session [1] Group 2: New Board Secretary Profile - Gao Yingying, born in 1994, is a Chinese national with no permanent residency abroad and is currently pursuing a Master's degree in Business Administration at Shanghai Normal University [1] - Her previous experience includes roles as a planner, host, director, and editor at various broadcasting stations from 2016 to 2022, and as a promotion director at Zhongshan Anxin New Retail Co., Ltd. from November 2022 to November 2025 [1]

睿智医药12月1日公告，公司董事会于近日收到董事会秘书许剑的书面辞职报告，许剑因工作调整原因 申请辞去公司董事会秘书职务，辞职报告自送达董事会之日起生效，辞职后将继续担任公司子公司上海 睿智医药研究集团有限公司投资发展部副总裁职务。公司于2025年12月1日召开第六届董事会第十四次 会议，审议通过了《关于变更董事会秘书的议案》，聘任高莹莹担任公司董事会秘书，任期自本次董事 会审议通过之日起至公司第六届董事会届满之日止。 ...

证券日报网讯12月1日，睿智医药（300149）在互动平台回答投资者提问时表示，公司最新获取的股东 名册显示，截至2025年11月20日，公司的股东总户数为39，753户。 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-79 睿智医药科技股份有限公司 传真：0750-3869666 电子邮箱：ir@chempartner.com 关于变更董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）董事会于近日收到公司董事 会秘书许剑先生提交的书面辞职报告，许剑先生因工作调整原因，申请辞去公司 董事会秘书职务，辞职报告自送达董事会之日起生效，其辞职后将继续担任公司 子公司上海睿智医药研究集团有限公司投资发展部副总裁职务。 许剑先生原定任期至公司第六届董事会届满为止。截至本公告披露日，许剑 先生持有公司 2025 年限制性股票激励计划中已授予但尚未归属的第二类限制性 股票 1,000,000 股，公司将按第二类限制性股票的相关法律法规及公司股权激励相 关规定办理。除此之外，许剑先生未持有公司股票，亦不存在应当履行而未履行 的承诺事项。许剑先生在担任董事会秘书期间恪尽职守、勤勉尽责，在公司规范 治理、合规信息披露以及维护投资者关系等方面发挥了重要作用。公司及董事会 对许 ...

1、审议通过了《关于变更董事会秘书的议案》 因工作调整原因，许剑先生申请辞去董事会秘书职务，仍继续担任公司子 公司其他职务，辞职报告自送达董事会之日起生效。经公司董事长WOO SWEE LIAN先生提名，董事会同意聘任高莹莹女士担任公司董事会秘书，任期自本次 董事会审议通过之日起至公司第六届董事会届满之日止。高莹莹女士已取得深 圳证券交易所颁发的《上市公司董事会秘书培训证明》，任职资格符合相关要 求。 本议案已经公司独立董事专门会议审议通过。具体内容详见公司同日在 巨潮资讯网（www.cninfo.com.cn）上披露的相关公告。 本议案以6票同意，0票反对，0票弃权获得通过。 证券代码：300149 证券简称：睿智医药 公告编号：2025-78 睿智医药科技股份有限公司 第六届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第六届董事会第十四次会 议于 2025 年 12 月 1 日以通讯方式召开。会议通知以书面、电话或电子邮件方 式送达。会议应到董事 6 人，实到 6 人。会议由公司董 ...

Core Viewpoint - The strategic cooperation between Fosun Pharma and Ruizhi Pharma aims to enhance drug development efficiency and quality, thereby solidifying Fosun Pharma's competitive advantage in the innovative pharmaceutical sector [1] Company Summary - Fosun Pharma's Senior Vice President and CEO of Global R&D Center, Li Xiang, highlighted the potential for improved efficiency and quality in drug development through collaboration with Ruizhi Pharma [1] - The partnership is expected to accelerate the transformation of innovative results into practical applications, reinforcing Fosun Pharma's position in the innovative medicine field [1] Industry Summary - The collaboration sets a benchmark for the industry by exemplifying a model of "innovation entity + service platform," which is anticipated to facilitate efficient integration of resources across the pharmaceutical supply chain [1] - This partnership aims to elevate the overall level of new drug development in China, ultimately providing more high-quality treatment options for patients [1]